Regeneron (REGN) Gets a Hold Rating from Cowen & Co.

By Jason Carr

Cowen & Co. analyst Yaron Werber maintained a Hold rating on Regeneron (REGNResearch Report) today and set a price target of $353. The company’s shares closed on Friday at $309.18, close to its 52-week low of $287.66.

According to, Werber is a 4-star analyst with an average return of 12.4% and a 61.4% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Prevail Therapeutics Inc.

Currently, the analyst consensus on Regeneron is a Hold with an average price target of $385.

See today’s analyst top recommended stocks >>

Regeneron’s market cap is currently $33.9B and has a P/E ratio of 14.63. The company has a Price to Book ratio of 3.59.

Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.